Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MAP2K1 E102_I103del |
| Therapy | Ulixertinib |
| Indication/Tumor Type | histiocytosis |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MAP2K1 E102_I103del | histiocytosis | predicted - sensitive | Ulixertinib | Case Reports/Case Series | Actionable | In a clinical case study, Ulixertinib (BVD-523) treatment resulted in 2 partial responses and 2 complete responses among 4 patients with histiocytosis, including Erdheim-chester disease and Langerhans cell histiocytosis, harboring MAP2K1 E102_I103del (PMID: 41135521). | 41135521 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41135521) | RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. | Full reference... |